Business
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation\n \n \nbiOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation\n\nOne of the most challenging aspects of treating Lysosomal Storage Diseases is the transport of the required enzymes across the Blood-Brain Barrier and into the Central Nervous System.\n\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sep 18, 2014) - BIOASIS TECHNOLOGIES INC. (TSX VENTURE:BTI)(OTCQX:BIOAF), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (\"BBB\"), announces a study to investigate the ability of its Transcend BBB transport platform technologies to deliver to the Central Nervous System of a knockout animal model, the therapeutic enzyme required to correct the neurological disorder, MPS II, or Hunter Syndrome. The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation (\"B4B\") of Padova, Italy, headed by renowned Lysosomal Storage Disease expert, Dr. Maurizio Scarpa, Founder and President of the Foundation. The study will be performed at the \"Diagnosis and Therapy of Lysosomal Disorders\" research facility of the University of Padova, and will be coordinated by Dr. Rosella Tomanin. \n The human enzyme to be administered in the study, Idursulfase (I2S), is missing or functionally deficient in human sufferers of Hunter Syndrome. The study will use a knockout animal model that has shown the same characteristics as in the human form of MPS II. The study will demonstrate whether a therapeutic quantity of I2S can be delivered in the animal's brain using biOasis' fusion proteins, MTf-I2S and the Transcend peptide-based MTfp-I2S, and whether the proteins can restore normal I2S function after intravenous administration.\n Through the mechanism of Receptor Mediated Transcytosis, the biOasis fusion proteins, MTfp-I2S and MTf-I2S, are designed to cross the BBB and to allow the I2S to localize in the lysosomes of brain cells. The study will allow biOasis and B4B to not only study the effects of the fusion MTfp and MTf proteins on the restoration of enzymatic activity, but also the effect of the proteins' administration in brain parenchyma cells a...